

FIRST HALF-YEAR 2010 RESULTS

EXCELLENT 1ST HALF-YEAR 2010 PERFORMANCE BY STALLERGENES

- **GROWTH IN FRANCE AND INTERNATIONALLY** **+13%**
- **VERY STRONG NET PROFIT GROWTH** **+51%**
- **FREE CASH FLOW GROWTH** **+90%**

Antony, France; 26 August 2010 – 6pm.

The Board of Directors' approved the 2010 half-year financial statements at its meeting of 25 August 2010, chaired by Albert SAPORTA:

In €m	H1 2009		09/08	H1 2010		10/09
		%CA	Var.%		%CA	Var.%
Sales	97.6	100.0	12	110.6	100.0	13
Cost of goods sold	(22.5)	(23.1)	13	(24.1)	(21.8)	7
SG&A	(37.8)	(38.8)	8	(43.9)	(39.7)	16
Profit before R&D	37.3	38.2	16	42.7	38.6	14
R&D costs	(21.3)	(21.8)	30	(16.6)	(15.0)	(22)
R&D revenues	3.6	3.7	35	3.5	3.2	(2)
EBIT	19.6	20.1	7	29.5	26.7	51
Net result, group share	13.4	13.7	11	20.2	18.2	51
EBITDA	24.1	24.7	12	35.6	32.2	48
Capital expenditure	9.4	9.6	93	6.9	6.3	(26)
Free cash flow	14.5	14.9	45	27.6	24.9	90
Net cash	1.3		ns	25.0		ns
Working capital	9.9		(16)	4.4		(55)
EPS, diluted	1.01 €		11	1.50 €		49

Sales growth and financial position

Sales grew by 13% in the first half-year. This significant increase reflected the continuing advancement of sublingual treatments, in particular buoyant Oralair® sales in Germany.

Under the combined effect of this growth and the temporary reduction in R&D expenditure, a significant increase in earnings was achieved in the 1st half-year 2010. Overall, the profit before R&D rose moderately in relative value and represented 38.6% of sales, compared to 38.2% in the 1st half-

year 2009. R&D expenditure fell very significantly by 22% in the first half-year and went from 21.8% of sales in 2009 to 15.0% this year. This decline was due to a timing difference between the end of the clinical studies in progress (and particularly the Oralair® study in the US) and the start of new studies. Operating profit rose by 51% to € 29.5 million. The net diluted earnings per share grew by 49% to € 1.50.

EBITDA grew by 48% to € 35.6 million. Investments temporarily fell by 26% over the half-year to € 6.9 million. As a result, and also due to stable working capital requirements, free cash flow recorded a significant 90% increase to € 27.6 million.

At 30 June, net cash resources grew from € 1.3 million in 2009 to € 25.0 million in 2010.

The half-year financial report can be downloaded from the website: <http://www.stallergenes.com>

At its meeting of 25 August 2010, the Board of Directors authorised the implementation of the share buyback programme approved by the Annual General Meeting of 28 May 2010, which will not exceed € 10 million and will more particularly be used to cover stock options and performance-based share payments.

Significant recent transactions and events

The positive clinical results achieved over the first half-year, in particular for Oralair® and Actair® lead us to consider our international expansion with confidence. These results are particularly encouraging in our drive to enter into strategic partnerships.

Oralair®, which is already marketed in Germany, will be launched in the autumn in the Netherlands, the Czech Republic, Slovakia and Austria. The market access process is ongoing in Southern European countries. In France more specifically, talks have been initiated with the “Commission de Transparence”, which should issue a public opinion by the end of the year.

R&D expenditure will recover in the second half-year but the 2010 total will not exceed the 2009 level in absolute value. Against this background, and considering projected sales growth in excess of 10%, the Group expects a significant increase in its full-year operating margin.

The recovery in investment in the second half should only have a marginal effect on the generation of free cash flow, which will be significantly greater in the full year 2010 than in 2009.

The presentation of the 2010 half-year results and outlook for the Group will take place on 27 August 2010 at 11.30 am (CET) at Hotel Le Bristol, 112, rue du Faubourg Saint-Honoré, 75008 Paris, France. This meeting will be webcast and will be available both in French and English on our website: <http://finance.stallergenes.com> from 3 pm.

ABOUT STALLERGENES

Stallergenes is a European biopharmaceutical laboratory specialising in treatments by immunotherapy for the prevention and treatment of allergy-related respiratory conditions, such as rhino conjunctivitis, rhinitis and allergic asthma. A pioneer and a leader in immunotherapy treatments by sublingual administration, Stallergenes dedicated more than 20% (gross) of its sales in 2009 to its Research and Development activities, which are primarily directed at developing a new therapeutic range enabling the provision of immunotherapy treatments by sublingual tablets. Stallergenes achieved 2009 sales of € 193 million, with over 500,000 patients treated with Stallergenes products.

Euronext Paris (Compartment B)
SBF 120 index.

ISIN code: FR0000065674
Reuters code: GEN.PA
Bloomberg code: GEN.FP



For further information, please visit our website: <http://www.stallergenes.com>

Contacts

Albert Saporta, Chairman and CEO

Tel. +33 1 55 59 20 04

Christian Thiry, Chief Financial Officer

Tel. +33 1 55 59 20 95

e-mail: investorrelations@stallergenes.fr

Investor and Analyst Relations

Lucile de Fraguier, Pavie Finance

Tel. +33 1 42 15 04 39

e-mail: contact@pavie-finance.com

Stallergenes Press Relations

Lise Lemonnier, Communication Officer

Tel. + 33 1 55 59 20 96

e-mail: llemonnier@stallergenes.fr